https://www.selleckchem.com/ph....armacological_epigen
Introduction Nabiximols, a cannabinoid-based oromucosal spray, is indicated as add-on therapy for symptomatic relief of spasticity in persons with multiple sclerosis (MS). This review compiles tolerability and safety data from clinical trials that investigated nabiximols for spasticity and/or chronic pain.Areas covered Systematic searches identified 38 placebo-controlled randomized controlled trials (RCTs) or post-RCT open-label studies reporting safety data 15 in spasticity; 16 in neuropathic pain; six in chronic cancer pain
Like
Comment
Share
